Novartis AG

NYSE

Market Cap.

237.03B

Avg. Volume

1.86M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Novartis AG

Novartis AG News

Novartis AG Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock
Website screenshot
HealthcareDrug Manufacturers - General
novartis.com

About Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG Earnings & Revenue

What’s This Company Really Worth? Find Out Instantly.

Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.

Novartis AG Financials

Table Compare

Compare NVS metrics with:

   

Earnings & Growth

NVS

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

NVS

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

NVS

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

NVS

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Novartis AG Income

Novartis AG Balance Sheet

Novartis AG Cash Flow

Novartis AG Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsBuy
Return on EquityStrong Buy
Return on AssetsStrong Buy
Debt/Equity RatioStrong Sell
Price/Earnings RatioSell
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Novartis AG Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

14.5976

Payment DateDividendFrequency
2025-04-253.994Quarterly
2024-04-193.7772Quarterly
2023-03-203.46936Quarterly
2022-03-173.357Quarterly
2021-03-153.378Quarterly

Historical Market Cap

Shares Outstanding

Novartis AG Executives

NameRole
Dr. Vasant Narasimhan M.D.Chief Executive Officer
Mr. Victor BultoPresident of US
Dr. Patrick Horber M.D.President of International
Mr. Harry KirschChief Financial Officer
Ms. Karen L. HaleChief Legal & Compliance Officer
NameRoleGenderDate of BirthPay
Dr. Vasant Narasimhan M.D.Chief Executive Officer19768.01M
Mr. Victor BultoPresident of USMale19784.27M
Dr. Patrick Horber M.D.President of International19704.06M
Mr. Harry KirschChief Financial OfficerMale19653.97M
Ms. Karen L. HaleChief Legal & Compliance OfficerFemale19682.56M

Discover More

Streamlined Academy

Novartis AG

NYSE

Market Cap.

237.03B

Avg. Volume

1.86M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Novartis AG News

Novartis AG Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock

Novartis AG Earnings & Revenue

Novartis AG Income

Novartis AG Balance Sheet

Novartis AG Cash Flow

Novartis AG Financials Over Time

Novartis AG Executives

NameRole
Dr. Vasant Narasimhan M.D.Chief Executive Officer
Mr. Victor BultoPresident of US
Dr. Patrick Horber M.D.President of International
Mr. Harry KirschChief Financial Officer
Ms. Karen L. HaleChief Legal & Compliance Officer
NameRoleGenderDate of BirthPay
Dr. Vasant Narasimhan M.D.Chief Executive Officer19768.01M
Mr. Victor BultoPresident of USMale19784.27M
Dr. Patrick Horber M.D.President of International19704.06M
Mr. Harry KirschChief Financial OfficerMale19653.97M
Ms. Karen L. HaleChief Legal & Compliance OfficerFemale19682.56M

Novartis AG Insider Trades

No data available

DateNameRoleTransactionTypeShares

No data available

Streamlined Academy

Website screenshot
HealthcareDrug Manufacturers - General
novartis.com

About Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Novartis AG

What’s This Company Really Worth? Find Out Instantly.

Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.

Novartis AG Financials

Table Compare

Compare NVS metrics with:

   

Earnings & Growth

NVS

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

NVS

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

NVS

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

NVS

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Novartis AG Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

14.5976

Payment DateDividendFrequency
2025-04-253.994Quarterly
2024-04-193.7772Quarterly
2023-03-203.46936Quarterly
2022-03-173.357Quarterly
2021-03-153.378Quarterly

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsBuy
Return on EquityStrong Buy
Return on AssetsStrong Buy
Debt/Equity RatioStrong Sell
Price/Earnings RatioSell
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More

The Secret to Analyzing Winning Stocks (Step-by-Step Examples Inside)